REVIEW ARTICLE


Vaccination Schedules and COVID-19 Risk



Mohamed Farouk Allam1, *, Fady Andraous1, Ghada Essam El-Din Amin1
1 Department of Family Medicine, Faculty of Medicine, Ain Shams University, El-Abaseya, Egypt


Article Metrics

CrossRef Citations:
1
Total Statistics:

Full-Text HTML Views: 2022
Abstract HTML Views: 1159
PDF Downloads: 858
ePub Downloads: 479
Total Views/Downloads: 4518
Unique Statistics:

Full-Text HTML Views: 1085
Abstract HTML Views: 578
PDF Downloads: 608
ePub Downloads: 283
Total Views/Downloads: 2554



Creative Commons License
© 2020 Allam et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at Department of Family Medicine, Faculty of Medicine, Ain Shams University, Egypt; Tel/Fax: + (2) 011 43 55 99 46; E-mail: farouk.allam@med.asu.edu.eg


Abstract

A significant difference in the number of novel coronavirus 2019 (COVID-19) cases and mortality has been noted among different World Health Organization (WHO) regions and countries. We compared the vaccination schedules for 2 countries from WHO Europe Region (Italy and Spain) and 2 countries from WHO Regional Office for the Eastern Mediterranean (Iran and Egypt). Both Iran and Egypt included the Sabin vaccine as part of the obligatory vaccination programs; meanwhile, Italy and Spain used the Salk vaccine. Recently, Iran and Egypt added a single dose of the Salk vaccine to the 6-7 doses of Sabin vaccine because of the new evidence showing that the use of the Salk vaccine in conjunction with Sabin vaccine achieves better mucosal immunity. Italy and Spain used an acellular vaccine against pertussis. Meanwhile, Iran and Egypt used a whole-cell vaccine. Taking into consideration the lower number of deaths in Iran and Egypt compared to Italy and Spain, we could hypothesize that the whole-cell pertussis vaccine could have a cross-immunity against COVID-19. Further research is warranted to identify the main reasons for the lower number of COVID-19 cases and deaths in certain countries in order to control COVID-19.

Keywords: Coronavirus, COVID-19, Pertussis, BCG, Measles, Vaccine, Review.